

Resource Summary Report

Generated by [NIF](#) on Sep 22, 2026

B-CPAP

RRID:CVCL_0153

Type: Cell Line

Proper Citation

RRID:CVCL_0153

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0153

Proper Citation: RRID:CVCL_0153

Description: Cell line B-CPAP is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Poorly differentiated thyroid gland carcinoma

Defining Citation: [PMID:1297527](#), [PMID:8156527](#), [PMID:11439348](#), [PMID:14522906](#), [PMID:15172756](#), [PMID:17725429](#), [PMID:17804723](#), [PMID:18713817](#), [PMID:19087340](#), [PMID:20164919](#), [PMID:21868764](#), [PMID:22087789](#), [PMID:22460905](#), [PMID:23162534](#), [PMID:23833040](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28775782](#), [PMID:30737244](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:32666385](#), [PMID:35839778](#)

Comments: Caution: Originally classified a thyroid gland papillary carcinoma (PTC) but is now considered to be a poorly differentiated thyroid gland carcinoma (PDTTC) (PubMed=23162534)., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: B-CPAP

Synonyms: BC-PAP, BCPAP

Cross References: BTO:BTO_0004736, CLO:CLO_0001906, MCCL:MCC:0000045, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

BioSample:SAMN03471001, BioSample:SAMN10989558, cancercellines:CVCL_0153, CCRID:3101HUMSCSP543, Cell_Model_Passport:SIDM00992, ChEMBL-Cells:ChEMBL3308356, ChEMBL-Targets:ChEMBL1075394, CLS:305081, Cosmic:755292, Cosmic:849970, Cosmic:924104, Cosmic:928836, Cosmic:931241, Cosmic:1084279, Cosmic:1162847, Cosmic:1237447, Cosmic:1239965, Cosmic:1280047, Cosmic:1507369, Cosmic:1533552, Cosmic:1536122, Cosmic:1889007, Cosmic:2036692, Cosmic:2054086, Cosmic:2319847, Cosmic:2613253, Cosmic:2791089, Cosmic-CLP:924104, DepMap:ACH-000456, DSMZ:ACC-273, DSMZCellDive:ACC-273, EGA:EGAS00001000978, GDSC:924104, GEO:GSM886875, GEO:GSM887940, GEO:GSM1669612, IARC_TP53:25011, LiGeA:CCLE_362, LINCX_LDP:LCL-1687, NCBI_Iran:C596, PharmacDB:BCPAP_82_2019, PRIDE:PXD030304, Progenetix:CVCL_0153, PubChem_Cell_line:CVCL_0153, Wikidata:Q54752132

ID: CVCL_0153

Record Creation Time: 20220427T215230+0000

Record Last Update: 20260920T012023+0000

Ratings and Alerts

No rating or validation information has been found for B-CPAP.

No alerts have been found for B-CPAP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Arawker MH, et al. (2026) STAT1-TCTN3 axis drives papillary thyroid carcinoma progression by accelerating the cell cycle and promoting tumor cell migration and invasion. International journal of biological macromolecules, 344(Pt 1), 150436.

Dal' Bó IF, et al. (2026) Roundup® Original DI promotes proliferation in papillary thyroid carcinoma cells: a comparative study highlighting cell-type-dependent effects. Frontiers in endocrinology, 17, 1745247.

Yu J, et al. (2026) Investigating the Role of TNFSF12 in Thyroid Cancer Progression via Single-Cell RNA Sequencing and Integrated Multiomics Analyses. Mediators of inflammation, 2026(1), e4753653.

Lv C, et al. (2026) circPTPRM can encode a functional polypeptide circPTPRM-187aa to promote papillary thyroid carcinoma progression. Molecular and cellular endocrinology, 614, 112734.

Bó IFD, et al. (2026) Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High-Dose Effects Challenge Regulatory Thresholds. *Journal of applied toxicology : JAT*.

Cui T, et al. (2026) PDE4C stabilized by ELAVL1 promotes lymph node metastasis in papillary thyroid cancer. *American journal of cancer research*, 16(2), 639.

Jiang L, et al. (2026) Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1313.

Cirello V, et al. (2025) TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer. *The Journal of clinical endocrinology and metabolism*.

Han Y, et al. (2025) TGF- β 1-based restoration of sodium iodide symporter expression in radioiodine-refractory differentiated thyroid cancer via engineered MSCs. *Molecular therapy : the journal of the American Society of Gene Therapy*, 33(12), 6130.

Cao Z, et al. (2025) Serum small extracellular vesicles-derived BST2 as a biomarker for papillary thyroid microcarcinoma promotes lymph node metastasis. *Cancer gene therapy*, 32(1), 38.

Kellett MD, et al. (2025) Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. *Frontiers in oncology*, 15, 1252544.

Ruan X, et al. (2025) Enhancer hijacking drives FAM20C expression to promote papillary thyroid cancer progression. *Cancer gene therapy*, 32(8), 854.

Gong Z, et al. (2024) Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. *Journal of endocrinological investigation*, 47(5), 1271.

Manso J, et al. (2024) Anti-Proliferative and Anti-Migratory Activity of Licorice Extract and Glycyrrhetic Acid on Papillary Thyroid Cancer Cell Cultures. *International journal of molecular sciences*, 25(19).

Poyil PK, et al. (2024) PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects. *Molecular oncology*, 18(3), 691.

Manso J, et al. (2024) First Evidence of Mineralocorticoid Receptor Gene and Protein Expression in Rat and Human Thyroid Tissues and Cell Cultures. *International journal of molecular sciences*, 25(2).

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. *Cancer biology & therapy*, 25(1), 2332000.

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. *EBioMedicine*, 110, 105459.

Poyil PK, et al. (2023) Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling. *Molecular oncology*.

Chou CK, et al. (2023) Clinical Impact of Androgen Receptor-Suppressing miR-146b Expression in Papillary Thyroid Cancer Aggressiveness. *The Journal of clinical endocrinology and metabolism*, 108(11), 2852.